Browsing Tag
Beijing
33 posts
China’s fuel price cut exposes the demand weakness beneath the global oil shock
China is cutting fuel prices while oil supply risks persist. The real story is weaker demand, refinery pain and electric vehicle disruption.
EU says China trade relationship is unsustainable as Brussels prepares tougher policy response
Europe needs China, but not at any cost. Brussels now says the trade relationship is unsustainable before decisive June talks.
VNET Group (NASDAQ: VNET) rallies as CATL stake and 517 MW order book reset AI thesis
CATL is taking 38% of VNET for nearly $1 billion. Wholesale just passed retail. The question is whether China's AI capex cycle reaches the bottom line.
BAI Capital raises $600m in first close of new Asia growth fund
Asia growth capital is getting more selective. BAI Capital’s US$600M first close shows where disciplined investors may still see upside.
Trump leaves Taiwan arms sale undecided after Xi warning in Beijing talks
Taiwan needs deterrence. China wants restraint. Donald Trump’s arms sale pause turns one weapons package into an Indo Pacific credibility test.
Xi warns Trump on Taiwan as US and China push trade deals in Beijing
Trump and Xi are chasing trade stability. Taiwan remains the fault line that could still pull United States China ties into crisis.
Lavrov in Beijing as China and Russia coordinate on Iran war and Trump threatens 50% tariff over weapons shipment
China's Wang Yi condemned the US Iran port blockade as Russia's Lavrov visited Beijing, with a weapons shipment intelligence report deepening US-China friction.
Is Cathay General Bancorp (Nasdaq: CATY) a quiet bank stock to watch before earnings?
Cathay General Bancorp (Nasdaq: CATY) heads into April 22 earnings near its 52-week high. Read what matters next for this regional bank stock.
Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound?
Biocytogen’s NEOK002 IND clearance and Moonlight Bio deal highlight a platform-led oncology strategy. Read what it means for growth and sentiment.
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix